Tonix Pharmaceuticals Holding TNXP
Tonix Pharmaceuticals Holding Corp. · Nasdaq · Pharmaceutical Preparations
Price, last 58 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Nov. 11, 2026 | Seth Lederman Chief Executive Officer, director | Bought | 5,000 | $4.06 | $20,275 |
| Aug. 27, 2026 | Seth Lederman Chief Executive Officer, director · indirect | Bought | 2,000 | $13.79 | $27,580 |
| Aug. 20, 2026 | Richard H. Bagger director | Bought | 1,000 | $12.60 | $12,600 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 16 →Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedTonix Pharmaceuticals Q3 2026 Revenue of $17.2 Million Beats $16.3 Million Consensus, but GAAP EPS of -$2.89 Misses -$2.24 Estimate
Results of operations and financial condition · Other events
Other events
Other events · Financial statements and exhibits
Other events · Financial statements and exhibits